AllazoHealth

AllazoHealth offers AI-powered solutions to improve patient support programs and enhance pharmaceutical marketing by delivering personalized communications effectively. Founded in 2011 and based in New York, US, AllazoHealth specializes in leveraging patient-level data for healthcare solutions. The company has a history of focusing on medication nonadherence and has made strategic decisions to enhance its offerings over time. The founder has a background that includes experience in the healthcare technology sector, although specific details on previous ventures are not publicly available.

As of now, AllazoHealth has completed 1 deal, with the most recent one occurring on April 2, 2025. AllazoHealth specializes in AI-powered solutions designed to enhance patient support programs and pharmaceutical marketing efforts. Their primary offering leverages patient-level data to deliver personalized communications, targeting the right patients with the right messages through optimal channels and timing. The platform facilitates improved therapy initiation, adherence, and overall health outcomes by utilizing insights from a dataset of 29 million de-identified patients.

The company focuses on various customer segments, including pharmaceutical companies and healthcare providers, aiming to address the challenges of medication nonadherence, which affects a significant portion of the patient population. AllazoHealth's products are primarily marketed within the United States but are also applicable in other regions where healthcare providers seek to enhance patient engagement through advanced data analytics and personalized outreach. AllazoHealth generates revenue through partnerships and B2B subscriptions that provide access to its AI-driven solutions. Clients typically engage in contractual agreements whereby they pay for services that enhance their patient support initiatives and pharmaceutical marketing strategies.

The structure involves recurring subscription fees that grant clients access to the platform’s capabilities, including predictive analytics and tailored communication strategies. This transactional model allows for continuous support and updates to the AI technology, enabling clients to improve their patient engagement efforts effectively. Specific pricing plans for AllazoHealth's services are not publicly disclosed, but the company emphasizes the value delivered through measurable improvements in therapy initiation rates and operational efficiencies. In April 2025, AssistRx, Inc.

, a portfolio company of Welsh, Carson, Anderson & Stowe, acquired AllazoHealth, although financial terms were not disclosed. This acquisition aims to expand and enhance AssistRx's patient engagement solution offerings. Future growth initiatives will involve developing new products and potential expansion into new geographic markets, leveraging the resources and capabilities of AssistRx to bolster AllazoHealth’s existing solutions.